• Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

    Pancreatic Cancer Patients with BRCA Mutation May Benefit from Targeted Drug

    Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

  • Daruka Mahadevan, MD, PhD, and Eric Weterings, PhD

    Immunotherapy: Harnessing the Power of the Immune System

    Designer antibodies, such as checkpoint inhibitors, have revolutionized cancer treatment.

  • HPV infographic

    UA Cancer Center Endorses Goal to Eliminate HPV-Related Cancers in U.S.

    Joint statement empowers parents, young adults and physicians to increase vaccination rates and screenings to eliminate HPV-related cancers, starting with cervical cancer.

Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.
Daruka Mahadevan, MD, PhD, and Eric Weterings, PhD
HPV infographic
Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

Pancreatic Cancer Patients with BRCA Mutation May Benefit from Targeted Drug

Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

Daruka Mahadevan, MD, PhD, and Eric Weterings, PhD

Immunotherapy: Harnessing the Power of the Immune System

Designer antibodies, such as checkpoint inhibitors, have revolutionized cancer treatment.

HPV infographic

UA Cancer Center Endorses Goal to Eliminate HPV-Related Cancers in U.S.

Joint statement empowers parents, young adults and physicians to increase vaccination rates and screenings to eliminate HPV-related cancers, starting with cervical cancer.

News Stories

Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

The company targets accelerated diagnosis and treatment of cancer by providing optimal tissue samples for effective personalized medicine.

Designer antibodies, like checkpoint inhibitors, have revolutionized cancer treatment.